RLXXF
RELX PLC
$33.45
0.00%
No data for this timeframe.
Vol
SEC Reports6
Recent Activity
Jun 1, 2026
SEC
RELX PLC filed a Form 6-K announcing the Euro equivalent of its 2025 final dividend of 48.0 pence per share, payable on
6-K — Impact 2/10
May 26, 2026
SEC
RELX PLC announces a £150 million non-discretionary share buyback programme running from May 26 to June 8, 2026, followi
6-K — Impact 3/10
May 1, 2026
SEC
RELX PLC filed a 6-K summarizing routine April 2026 share buyback transactions, a block admission for employee share pla
6-K — Impact 2/10
Analyst Ratings
9Strong Buy
12Buy
2Hold
1Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.3/10.
NEUTRAL
6-K
2/10
RELX PLC filed a Form 6-K announcing the Euro equivalent of its 2025 final dividend of 48.0 pence pe
Jun 1, 2026
NEUTRAL
6-K
3/10
RELX PLC announces a £150 million non-discretionary share buyback programme running from May 26 to J
May 26, 2026
NEUTRAL
6-K
2/10
RELX PLC filed a 6-K summarizing routine April 2026 share buyback transactions, a block admission fo
May 1, 2026
NEUTRAL
6-K
3/10
RELX PLC held its 2026 Annual General Meeting on April 23, where shareholders approved all 21 resolu
Apr 23, 2026
NEUTRAL
6-K
4/10
RELX PLC announced a non-discretionary share buyback program to repurchase $350 million of its ordin
Apr 23, 2026
BULLISH
6-K
6/10
RELX PLC issued a trading update ahead of its Annual General Meeting, reaffirming strong full-year g
Apr 23, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 88% buy across 24 analysts — 9 strong buy, 12 buy, 2 hold, 1 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $10.1B | 5.8% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $10.8B | 6.3% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 12 | 2 | 1 | 0 | 88% | |
| May 1, 2026 | 9 | 14 | 1 | 1 | 0 | 92% | |
| Apr 1, 2026 | 8 | 14 | 2 | 1 | 0 | 88% | |
| Mar 1, 2026 | 8 | 14 | 2 | 1 | 0 | 88% | |
| Feb 1, 2026 | 6 | 14 | 4 | 0 | 0 | 83% | |
| Jan 1, 2026 | 6 | 14 | 3 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.